Portal de Periódicos da CAPES

Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2

2008; Wiley; Volume: 99; Issue: 8 Linguagem: Inglês

10.1111/j.1349-7006.2008.00867.x

1349-7006

Takashi Kasukabe, Junko Okabe‐Kado, Yoshio Honma,

PI3K/AKT/mTOR signaling in cancer

Cotylenin A, a plant growth regulator, and rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), are potent inducers of differentiation of myeloid leukemia cells. Recently, we found that cotylenin A and rapamycin effectively inhibited the proliferation of several human breast cancer cell lines including MCF‐7. Herein, we demonstrate that cotylenin A and rapamycin rapidly and markedly induced the cyclin G2 gene expression in several cancer cells including MCF‐7 cells. The growth arrest of the MCF‐7 cells at the G1 phase, induced by the treatment with cotylenin A and rapamycin or the culture in low serum medium, markedly induced the cyclin G2 gene expression. Anticancer drugs including doxorubicin, etoposide and 5‐fluorouracil also induced cyclin G2 expression during induction of growth arrest of the MCF‐7 cell at the G1 phase or G2/M phase. Ectopically inducible cyclin G2 expression potently inhibited the proliferation of MCF‐7 cells. Furthermore, cyclin G2 knockdown induced by cyclin G2 small interfering RNA markedly reduced the potency of cotylenin A plus rapamycin to induce growth inhibition. Taken together, our results suggest that cotylenin A and rapamycin induce inhibition of cancer cell growth through the induction of cyclin G2. ( Cancer Sci 2008; 99: 1693–1698)